Abstract library

296 results for "resectable pnets".
#2243 Somatostatin Analogs (SSAs) as Effective Treatment of Resectable, non Metastatic, non Functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Patients Unfit for Surgery. A Case Series.
Introduction: SSAs are used to treat symptomatic functioning pNETs and to prolong progression free survival in metastatic, G1/G2, somatostatin receptor-positive pNETs. Pancreatic surgery is burdened with important morbidity and mortality, especially in patients with increased anaesthesiological risk.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Chiara Nessi
Authors: Nessi C, Paiella S, Miotto M, Viviani E, ...
#808 Characteristics and Determinants of Long-Term Outcome for Resectable Sporadic Non-Functional Pancreatic Neuroendocrine Tumors (NF-PNETs): Updated 16-year Experience from Two Large Chinese Centers
Introduction: Non-functional pancreatic neuroendocrine tumors (NF-PNETs) are increasingly recognized with unique biology.
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: M.D. Xu Han
Authors: Jin G, Han X, Jin D, Hu X, ...
Keywords: NF-PNETs
#1348 Resectable Primary Tumor in Patients with Pancreatic Neuroendocrine Tumors Located to the Body or Tail and Unresectable Liver Metastases: Does Distal Pancreatectomy Improve Survival?
Introduction: The role of primary tumor surgery in pancreatic neuroendocrine tumor (PNET) with unresectable liver metastases is controversial and international guidelines do not recommend surgery in that setting of patients
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Dr Emilio Bertani
Authors: Bertani E, Fazio N, Grana C, Chiappa A, ...
#593 The Combination of CK19 and KIT is a Potential Predictor for Clinical Behaviors and Postoperative Outcomes in Resectable Pancreatic Neuroendocrine Tumors
Introduction: We assumed that pNETs is a disease triggered by the re-activation of developmental signaling pathways, once again expressing KIT and CK19.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Xu Han
Authors: Han X, Zhao J, Ji Y, Xu X, ...
Keywords: pNET, CK19, KIT
#816 Resection at Diagnosis of the Primary Pancreatic Neuroendocrine Tumor in Patients with Unresectable Liver Metastases. A Possible New Approach for a Multimodal Treatment
Introduction: Pancreatic neuroendocrine tumors (PNETs) present in more than 50% of cases with liver metastases as the only systemic localization. Liver metastases are unresectable in 80% of cases at diagnosis. In the context of metastatic disease, the benefit of primary tumor removal in terms of survival is controversial
Conference: 11th Annual ENETS Conference (2014)
Category: Surgical treatment
Presenting Author: Emilio Bertani
#1240 Targeted Therapies as First Line Option in Very Advanced Unresectable Pancreatic Neuroendocrine Tumors
Introduction: Neuroendocrine tumors are an entity of rare, heterogeneous group of tumors that can arise from different sites within the body. Although number of different treatment types and modalities exist, chemotherapy remains as the first line option in the management of advance pancreatic NETS (pNETS); two targeted therapies, sunitinib and everolimus remains available only for second line and beyond in Canada.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Young Soo Rho
Authors: Rho Y S, Gilabert M, McLean J, Kavan P, ...
#831 Overall Survival (OS) as a Function of the Number of Therapeutic Lines in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors (WDpNET)
Introduction: At least 9 therapeutic options are now available for unresectable WDpNET patients. Whether all lines can be administrated before tumor or toxic-related deaths is currently unknown.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Amandine Berdelou
Keywords: pNets
#1336 Resection of the Primary Tumor Prior to Peptide Receptor Radionuclide Therapy Improves Treatment Response and Progression-free Survival in Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases
Introduction: A low burden of disease represents an independent favorable prognostic factor of response to peptide receptor radionuclide therapy (PRRT) in patients affected by gastro-entero-pancreatic neuroendocrine tumors. However it is not clear whether this is due to a lower diffusion of the disease or thanks to debulking surgery
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Emilio Bertani
Authors: Bertani E, Fazio N, Grana C, Bodei L, ...
#1842 OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET).
Introduction: OPALINE Study focuses on patients with pNET. Two targeted therapies (TT) offer new options to treat these patients: mTORi (everolimus) and a multi-targeted inhibitor (sunitinib).
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Julie Grellier de Heaulme
#1023 Streptozotocin/5-Fluorouracil (STZ/5FU) Chemotherapy in G1-G2 Pancreatic Neuroendocrine Tumors (pNETs): Single Institution Experience
Introduction: STZ is the only FDA-approved antiblastic drug for well-/moderately-differentiated NETs. To date, no clear therapeutic sequence is defined for medical treatment of advanced pNETs.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Sara Cingarlini
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.